News
2022
Oct 12
Wednesday, October 12, 2022
Dechra Announces Sponsorship with Not One More Vet (NOMV)
Dechra is proud to announce our recent sponsorship of Not One More Vet (NOMV) to spread awareness and provide supportive programs for mental wellbeing in the veterinary industry.
keyboard_arrow_right
Read more
2022
Jul 06
Wednesday, July 6, 2022
Dechra Introduces Zenalpha® (medetomidine and vatinoxan hydrochlorides injection) as Canine Sedative that Helps Minimize Cardiovascular Side Effects
Zenalpha is an innovative, new alpha-2 combination drug that minimizes the stress surrounding sedation in dogs while maximizing procedural efficiency.
keyboard_arrow_right
Read more
2022
May 24
Tuesday, May 24, 2022
Dechra Academy Launches New Courses on Canine Otitis Externa
Dechra is excited to launch two new course offerings on Dechra Academy, their on-demand educational platform, focusing on the diagnosis and treatment of canine otitis externa.
keyboard_arrow_right
Read more
2022
Apr 28
Thursday, April 28, 2022
Dechra acquires the rights to Zenalpha® (medetomidine and vatinoxan hydrochlorides injection)
Vetcare and Dechra announce the FDA approval of Zenalpha®
keyboard_arrow_right
Read more
2022
Apr 27
Wednesday, April 27, 2022
Dechra Announces VOHC Acceptance for Water Additive
Dechra Veterinary Products is pleased to announce that its VETRADENT® Liquid Water Additive has received the seal of acceptance to Help Control Tartar from the Veterinary Oral Health Council (VOHC). The seal has been granted for dogs after properly demonstrating both safety and efficacy.
keyboard_arrow_right
Read more
2022
Mar 04
Friday, March 4, 2022
Dechra acquires the rights to Malaseb®
Dechra is pleased to announce the licensing rights of the Malaseb® brand of dermatology products in the United States with Dermcare of Australia.
keyboard_arrow_right
Read more
2022
Jan 13
Thursday, January 13, 2022
Dechra acquires the rights to Laverdia™-CA1 (verdinexor tablets)
Dechra Veterinary Products is pleased to announce that Dechra has acquired the rights to Laverdia™-CA1 (verdinexor tablets) from Anivive Lifesciences, Inc.
keyboard_arrow_right
Read more
2022
Jan 07
Friday, January 7, 2022
Dechra acquires Isoflurane and Sevoflurane from Halocarbon Life Sciences
Dechra is pleased to announce the acquisition of the veterinary approved Isoflurane®, USP Inhalant Anesthetic and Sevoflurane®, USP Inhalant Anesthetic from Halocarbon.
keyboard_arrow_right
Read more
2022
Jan 04
Tuesday, January 4, 2022
Dechra announces partnership with Bioiberica to boost companion animal offering in the United States
Dechra is pleased to announce a joint collaboration with Bioiberica, a global Life Science company committed to improving the health and well-being of people, animals and plants, for the license and distribution of its Atopivet® range of dermatology products for cats and dogs in the United States.
keyboard_arrow_right
Read more
2021
Dec 03
Friday, December 3, 2021
DSM Biomedical and Dechra partner to fuel innovation in animal injury recovery
DSM Biomedical announces a joint collaboration with Dechra Limited for the license and distribution of devices that create isolated solutions of highly concentrated cells and / or platelets for use with horses and companion animals.
keyboard_arrow_right
Read more